Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that Chief Executive Officer Amir Reichman will co-lead a Manufacturers Association of Israel-organized roundtable discussion titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" during HealthIL Week 2026. The session, scheduled for January 19, 2026, at Expo Tel Aviv, will focus on Israel's biopharma development and manufacturing ecosystem, including early-stage development, CMC activities, and clinical manufacturing, as well as readiness for later-stage and commercial manufacturing.
The roundtable is expected to bring together representatives from government agencies, biopharma manufacturers, CDMOs, multinational pharmaceutical companies, biotech firms, and investors to examine current capabilities, structural gaps, and collaboration models shaping the sector's future. This gathering represents a significant opportunity for stakeholders across the biopharmaceutical value chain to assess Israel's position in the global manufacturing landscape and identify strategic pathways for growth and investment.
Scinai Immunotherapeutics operates through two complementary business units that reflect the dual focus of the upcoming discussion. Scinai Bioservices functions as a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide. Meanwhile, Scinai R&D focuses on developing innovative I&I therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.
The implications of this roundtable extend beyond the immediate participants to the broader biopharmaceutical industry. As global demand for biologics continues to grow, manufacturing capacity and capabilities have become critical bottlenecks in bringing innovative therapies to market. Israel has emerged as a significant player in biotechnology innovation, but questions remain about its manufacturing infrastructure's ability to support the transition from research to commercial production. The discussion will address these challenges directly, examining how Israel can leverage its scientific expertise to build a more robust manufacturing ecosystem.
For investors and industry observers, the roundtable represents an important opportunity to gauge Israel's competitive position in the global biopharma manufacturing landscape. The presence of multinational pharmaceutical companies alongside local biotech firms and government representatives suggests a recognition of Israel's potential as both a source of innovation and a manufacturing hub. The outcomes of this discussion could influence investment decisions, partnership opportunities, and policy initiatives aimed at strengthening Israel's biopharmaceutical sector.
The broader context of this announcement relates to increasing global competition in biopharmaceutical manufacturing, with countries and regions seeking to establish themselves as reliable partners in the production of complex biological therapies. As supply chain vulnerabilities have become more apparent in recent years, discussions about regional manufacturing capabilities have gained urgency. The roundtable at HealthIL Week 2026 will contribute to this global conversation while focusing specifically on Israel's unique opportunities and challenges.
Additional information about Scinai Immunotherapeutics is available in the company's newsroom at https://ibn.fm/SCNI. The full press release announcing the CEO's participation in the roundtable can be viewed at https://ibn.fm/dfb1F.
